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Background: Carbapenemase-producing organisms (CPO) have been largely responsible
for the extensive spread of carbapenem resistance, and their prevalence is increasing in
many parts of the world.
Aim: To evaluate clinical and molecular epidemiology and mortality associated with CPO
among patients.
Methods: All CPO from clinical and long-term healthcare surveillance cultures across
Scotland in 2003e2017 were reviewed retrospectively. Polymerase chain reaction was
used to detect genes coding for carbapenemases. A generalized linear mixed model was
used to identify risk factors for mortality.
Findings: In total, 290 individuals with CPO were identified. The overall incidence
increased over time (P<0.001) from 0.02 to 1.38 per 100,000 population between 2003 and
2017. A total of 243 distinct CPO isolates were obtained from 269 isolations in 214 indi-
viduals with available metadata. The majority of the isolates were Enterobacterales (206/
243, 84.8%), and Klebsiella pneumoniae (65/206, 31.6%) and Enterobacter cloacae (52/
206, 25.2%) were the most common species. VIM (75/243, 30.9%) and NDM (56/243, 23.0%)
were the most common carbapenemases. The crude 30-day mortality rate was 11.8% (25/
211), while the case fatality rate was 5.7% (12/211). Age >60 years [adjusted odds ratio
(aOR) 3.36, 95% confidence interval (CI) 1.06e10.63; P¼0.033], presence of non-Institute, University of
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S. Zhao et al. / Journal of Hospital Infection 110 (2021) 184e193 185fermenters (aOR 4.88, 95% CI 1.64e14.47; P¼0.005), and systemic infection or organ
failure (aOR 4.21, 95% CI 1.38e12.81; P¼0.032) were independently associated with 30-
day mortality.
Conclusion: The incidence of CPO in Scotland is low but increasing. Awareness is required
that inpatients aged >60 years, patients with systemic infection or organ failure, and
patients presenting with non-fermenters are at higher risk of death from CPO.
ª 2021 The Authors. Published by Elsevier Ltd
on behalf of The Healthcare Infection Society. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Over the past two decades, the emergence of carbapenem-
resistant organisms (CRO) has become a global public health
crisis, leaving few effective therapeutic options available to
treat multi-drug-resistant infections [1,2]. Resistance to car-
bapenems arises from two general mechanisms: carbapene-
mase production and non-enzymatic. CRO strains that do not
produce carbapenemases (non-enzymatic) are usually less
resistant to other antibiotics [3], and their carbapenem
resistance trait is not transferable. Carbapenemases, in con-
trast, are encoded by genes frequently carried on mobile
genetic elements such as plasmids and transposons, which
could be transferred between different species and individu-
als. Therefore, carbapenemase-producing organisms (CPO)
have largely been responsible for the rapid and extensive
worldwide spread of CRO, and are considered to be of more
clinical concern than non-enzymatic CRO.
With regard to the epidemiological stage of CPO, the UK is
reported to be in a ‘regional spread’ situation, while many
European countries are in an ‘inter-regional spread or
endemic’ situation, such as Italy, Greece, France, Poland and
Denmark [4]. In the UK, the prevalence and incidence of clin-
ically significant CPO is currently low, but these multi-drug-
resistant bacteria affect most UK regions [5]. In Scotland, the
first CPO was reported in an Enterobacter cloacae complex
blood culture isolate in 2003, carrying Klebsiella pneumoniae
carbapenemase-4 [6]. The prevalence of CPO in Scotland (0.1
per 100,000 patient-days) was lower than that in England and
Northern Ireland (0.85 per 100,000 patient-days) in healthcare
settings [7]. However, there has been a 39% year-on-year
increase in the prevalence of reported CPO isolates since
2013 in Scotland, from 0.4 per 100,000 population in 2013 to 2.0
per 100,000 population in 2017 [8]. The epidemiology of Scot-
tish CPO isolates, however, remains unclear. As such, this study
aimed to conduct a detailed analysis of epidemiological char-
acteristics of CPO in Scotland. Insights based on these findings
will further the development of effective and appropriate
prevention and infection control strategies, thus contributing
to curb future emergence and spread of CPO in Scotland.Methods
Ethics
All data for analyses in this study were anonymized. The
study was reviewed and approved by the Public Benefit and
Privacy Panel for Health and Social Care, and covered by
National Safe Haven generic ethics approval (Ref. No.
1617e0328). The study was conducted in accordance with theDeclaration of Helsinki, and national and institutional
standards.
Study design
A national retrospective observational study was conducted
among patients in Scotland between January 2003 and
December 2017. Specimens with suspected CPO from clinical
indications or a surveillance programme were submitted to a
Scottish diagnostic laboratory. Identification of isolates and
antimicrobial susceptibility tests were performed using
VITEK2 (bioMérieux, Marcy-l’Étoile, France) [5]. If the isolate
was non-susceptible to at least one carbapenem, the diag-
nostic laboratory referred the isolate to the Antimicrobial
Resistance and Healthcare-Associated Infections (AMRHAI)
Reference Unit at Public Health England (PHE) for confirmation
of carbapenemase production by in-house polymerase chain
reaction [5].
Definitions
In this article, samples have been described as cases, iso-
lations and isolates. A CPO case was defined as an individual
from whom there has been a CPO isolation. Each CPO isolation
was described on the basis of organism (e.g. K. pneumoniae),
enzyme (e.g. VIM), isolation date and specimen (e.g. urine).
Isolations that differ in any of these characteristics repre-
sented different isolations. For each CPO case, a CPO isolate
was defined on the basis of organism and enzyme; a difference
in either organism or enzyme represented different isolates.
Therefore, each CPO case could contribute multiple CPO iso-
lations with multiple CPO isolates. For one CPO case, if there
were multiple isolations of the same isolate from the same
specimen, only the first isolation was included in the study.
This method was used in order to assess the diversity of car-
bapenemases and independent specimen sources for statistical
analysis more uniformly. All cases were classified as
healthcare-associated (HA) or community-associated (CA)
[9,10] (Table S1, see online supplementary material). Speci-
men type of the isolations was aggregated into seven groups:
urine, alimentary, wound, normally sterile site, respiratory,
superficial, and site unspecified.
Data collection
The data used in this study were extracted from several
national datasets. Laboratory records were extracted from the
Electronic Communication of Surveillance in Scotland. Medical
records at individual level were extracted from the General
Acute Inpatient and Day Case e Scottish Morbidity Record.
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National Records of Scotland Deaths. Data extraction and
linkage of these datasets were performed by Public Health
Scotland via the electronic Data Research and Innovation
Service (eDRIS).
Outcomes and statistical analysis
The outcomes included:
(i) incidence of CPO, defined as the number of new CPO cases
per 100,000 population per year. Temporal trends in inci-
dence were investigated using an exponential model;
temporal trends in incidence of Enterobacterales and non-
fermenters were explored using a generalized linear
model, and differences in temporal trends in incidence
between Enterobacterales and non-fermenters were
examined by testing for an interaction between bacterial
family and isolation year. Temporal trends in incidence of
CPO source (HA and CA) and differences in temporal trends
in incidence between HA and CA cases were examined as
described above.
(ii) Mortality of CPO cases. Crude 30-day mortality rate,
defined as the number of deaths within 30 days of CPO
isolation per 100 cases; and case fatality rate (CFR),
defined as the number of CPO-attributed deaths per 100
cases.
(iii) Risk factors for 30-day mortality of CPO inpatient cases. A
generalized linear mixed model was used to determine the
risk factors. Independent variables included demo-
graphics, microbiological characteristics, comorbidities,
healthcare exposure and invasive procedures in the 90
days preceding CPO isolation. Definitions for each inde-
pendent variable are listed in Table S2 (see online
supplementary material).
Univariate analysis was performed first, and all variables
with P<0.10 were carried forward for multi-variate analysis.
Correlations between variables with P<0.10 on univariate
analysis were checked by calculating correlation coefficients.
Also, possible interactions between variables were checked.
Model averaging was used to construct the final multi-variate
model using the Akaike weights of the candidate models [11].
For statistical purposes, variables with zero values in either
group were removed from multi-variate analyses. Odds ratios
(OR) and 95% confidence intervals (95% CI) were calculated to
determine the strengths of these associations. All analyses
were performed using R Version 3.3.3, and P<0.05 was con-
sidered to indicate statistical significance.
Results
Overview of the study
Up to the end of 2017, a total of 290 cases were diagnosed
with CPO isolation from 13 of 14 Scottish National Health
Service boards. The metadata of cases identified in 2003 (N¼1)
and 2017 (N¼75) were not available, hence only 214 cases were
included in the subsequent analyses. Clinical characteristics of
CPO cases are listed in Table I. There were more female cases
(N¼112, 52.3%) than male cases (N¼102, 47.7%). The age of
CPO cases ranged from 0 to 92 years (median age 63 years,interquartile range 53e78 years). There was no difference in
age betweenmale and female cases (P¼0.838). Among 214 CPO
cases, 170 (79.4%) cases had a single isolation while 44 (20.6%)
cases had multiple isolations, resulting in 269 unique isolations.
One hundred and fifty-one (70.6%) of 214 cases were inpa-
tients. In total, 243 CPO isolates were obtained from 214 cases.
Due to incompleteness of the medical records for three CPO
cases, the CPO source could be classified for only 211 cases.
Among them, 149 (70.6%) were HA cases. Incidence rates of
both HA and CA increased significantly over time (P<0.001),
but no difference in temporal trends in incidence was found
between them (P¼0.310).
Incidence and mortality of CPO
Figure 1 shows the number of CPO cases and temporal trends
in incidence from 2003 to 2017. Overall incidence increased
between 2003 and 2017 (incidencew0.025*1.332̂year;
P<0.001) from 0.02 to 1.38 per 100,000 population. To evaluate
the impact of active surveillance for carbapenemase-
producing Enterobacterales (CPE) introduced in August 2013,
an exponential model was used to fit the data before
(2003e2013) its introduction. Before surveillance, the model
was incidencew0.021*1.330̂year. Incidence rates of Enter-
obacterales and non-fermenters increased significantly over
time (P<0.001), but the prevalence of Enterobacterales
(annual increase of 42.5%) increased faster than that of non-
fermenters (annual increase of 21.5%) (P¼0.001). The crude
30-day mortality rate was 11.8% (25/211) and CFR was 5.7%
(12/211).
Microbiological characteristics of CPO isolates
There were 269 unique CPO isolations. Urine (N¼103,
38.3%), alimentary (N¼55, 20.4%) and wound (N¼42, 16.0%)
specimens predominated at aggregate level, with urine (N¼99,
36.8%), rectal swabs (N¼45, 16.7%) and wound swabs (N¼32,
11.9%) being the most common specimens (Figure 2). In gen-
eral, the number of CPO isolations from wound, urine and ali-
mentary samples increased gradually. The majority of CPO
isolations were from urine and alimentary samples from 2013
onwards (Figure 3). The 243 CPO isolates were represented by
eight genera and 14 species; the majority were Enter-
obacterales (206/243, 84.8%), and K. pneumoniae (65/206,
31.6%), E. cloacae (52/206, 25.2%) and Escherichia coli (50/
206, 24.3%) were the most common species. Pseudomonas
aeruginosa (29/37, 78.4%) predominated among non-
fermenters (Figure 4). Carbapenemases comprised VIM (75/
243, 30.9%), NDM (56/243, 23.0%), KPC (43/243, 17.7%), OXA-48
(43/243, 17.7%), IMP (18/243, 7.4%), IMI (3/243, 1.2%),
NDMþIMP (2/243, 0.8%), NDMþOXA-48 (2/243, 0.8%) and GES-5
(1/243, 0.4%).
Risk factors for 30-day mortality of CPO inpatient
cases
There were 151 inpatient cases; of these, 23 (15.2%) died
within 30 days of CPO isolation. Univariate analysis indicated
that all-cause 30-day mortality was associated with advanced
age, presence of carbapenemase-producing non-fermenters,
sepsis, malignancy, respiratory tract infection, and systemic
Table I




Age (years), median (IQR,
range)
63 (53e78, 0e92)
Advanced age (>60 years) 124/211 (58.8)









Neoplasms and diseases of










Diabetes mellitus 21/211 (10.0)
With complications 8/211 (3.8)
Diseases of the circulatory
system
51/211 (24.2)
Heart failure 3/211 (1.4)
Diseases of the respiratory
system
53/211 (25.1)
Respiratory tract infection 33/211 (15.6)
Respiratory failure 5/211 (2.4)
Diseases of the digestive
system
21/211 (10.0)
Diseases of the genitourinary
system
58/211 (27.5)
Urinary tract infection 35/211 (16.6)
Renal failure 21/211 (10.0)
Diseases of the nervous
system
21/211 (10.0)







External causes of morbidity 53/211 (25.1)




Immunocompromised status 44/211 (20.9)
Healthcare exposure
HDU stay 58/211 (27.5)
Duration of HDU stay (days),
median (IQR, range)
0 (0e1, 0e65) for 211 cases
ICU stay 45/211 (21.3)
Duration of ICU stay (days),
median (IQR, range)
0 (0e0, 0e39) for 211 cases
Hospitalization 87/211 (41.2)
(continued on next page)
Table I (continued )
Characteristics N (%)a
Duration of hospitalization
(days), median (IQR, range)
8 (0e31.5, 0e91) for 211 cases
Hospital transfer 32/211 (15.2)
Ward transfer 97/211 (46.0)




Surgical specialty 69/150 (46.0)
TAR (days), median (IQR,
range)
6.5 (1e25, 0e91) for 150 cases










Urinary catheter 6/211 (2.8)
CVC 15/211 (7.1)
Dialysis or drainage 7/211 (3.3)
Endoscopic operation 17/211 (8.1)
Invasive ventilation 9/211 (4.3)
Other surgical procedures 26/211 (12.3)
ICU, intensive care unit; IQR, interquartile range; HDU, high depend-
ency unit; TAR, time at risk (defined as interval between admission to
hospital and CPO isolation); CVC, central venous catheter.
a Number of cases with the characteristic/total number of cases
investigated (percentage of cases with the characteristic), unless sta-
ted otherwise.
b Certain infectious and parasitic diseases comprise sepsis (including
septic shock), infections caused by CPO, and infections caused by other
pathogens (Clostridium perfringens, Clostridioides difficile, Strepto-
coccus spp., Staphylococcus spp, Salmonella spp., Aspergillus spp.,
Candida spp., human immunodeficiency virus, hepatitis C virus,
Reoviridae).
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showed that age>60 years [adjusted odds ratio (aOR) 3.36, 95%
CI 1.06e10.63; P¼0.033], presence of carbapenemase-
producing non-fermenters (aOR 4.88, 95% CI 1.64e14.47;
P¼0.005), and systemic infection or organ failure (aOR 4.21,
95% CI 1.38e12.81; P¼0.032) were independent risk factors for
30-day mortality (Table II).
Discussion
According to guidance from the European Centre for Disease
Prevention and Control, understanding and monitoring the
local epidemiological situation is necessary to implement and
refine CRO prevention and control strategies [12]. To date, no
comprehensive epidemiological study of CPO has been con-
ducted in Scotland at national or individual level. To the
authors’ knowledge, this is the first epidemiological study of
CPO in Scotland since it was first reported in 2003.
To date, there is no acknowledged definition of an episode
or de-duplication criterion for a CPO case. The longest interval




























Figure 1. Incidence of carbapenemase-producing organisms (CPO) in Scotland 2003e2017. Black circles represent the incidence of CPO,
and black lines represent the temporal trend in CPO incidence between 2003 and 2017. Green lines represent the temporal trend in CPO
incidence before conduction of Scottish carbapenemase-producing Enterobacterales active surveillance (i.e. between 2003 and 2013),
and green circles indicate the predicted incidence of CPO between 2014 and 2017 from the pre-surveillance model (2003e2013). The
vertical distance between black circles and green circles represents the difference between actual incidence and predicted incidence

























































Figure 2. Specimen types of 269 carbapenemase-producing organism (CPO) isolations according to aggregate specimen (inner circle) and
specific specimen (outer circle).






























Figure 3. Temporal distribution of aggregate specimen types of 269 carbapenemase-producing organism (CPO) isolations.
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study, indicating possible long-term persistence of CPO. As a
result, no definition of episodes was attempted in this study,
and the analysis was based on patients (i.e. CPO cases), using
the first isolation for patients with multiple CPO isolations,
unless stated otherwise. In 2013, Scotland launched an acute
hospital admission screening programme for CPE [13]. How-
ever, carbapenemase-producing non-fermenters from CPE
screening samples were also reported to Public Health Scotland















Figure 4. Family (inner circle), genus (middle circle) and species (oin CPO cases reported, particularly CPE, may reflect increased
awareness and testing due to the introduction of CPE screen-
ing, noting that: (i) the true incidence was higher than the
extrapolations from the model in 2003e2013 (Figure 1); (ii) the
incidence of Enterobacterales increased significantly faster
than that of non-fermenters; and (iii) most of the isolates were
from alimentary and urine samples which were usually used for
screening, and the number of isolates from these specimens
increased from 2013 (Figures 2 and 3). The prevalence of CPO


























uter circle) of 243 carbapenemase-producing organism isolates.
Table II






OR (95% CI) P-
value
aOR (95% CI) P-
value
Demographics
Age (years), median (IQR) 62 (49.5e74) 71 (61e78) 1.04 (1.00e1.07) 0.024
Age >60 years 69 (54.33) 18 (78.26) 3.03 (1.06e8.65) 0.039 3.36 (1.06e10.63) 0.033
Gender, male 73 (57.48) 12 (52.17) 0.81 (0.33e1.97) 0.637
Microbiological characteristics




57 (44.88) 8 (34.78) 0.65 (0.26e1.65) 0.371
Sepsis 11 (8.66) 6 (26.09) 3.72 (1.22e11.38) 0.021
Co-presence with other pathogens 20 (15.75) 1 (4.35) 0.24 (0.03e1.91) 0.179
Neoplasms and diseases of
the blood and blood-
forming organs
37 (29.13) 10 (43.48) 1.87 (0.75e4.64) 0.177
Malignancy 24 (18.90) 9 (39.13) 2.76 (1.07e7.12) 0.036 1.57 (0.49e5.09) 0.081
Solid 8 (6.30) 3 (13.04) 2.23 (0.55e9.13) 0.264
Haematologic 16 (12.60) 6 (26.09) 2.45 (0.84e7.13) 0.100
Anaemia 7 (5.51) 2 (8.70) 1.63 (0.32e8.40) 0.558
Endocrine, nutritional and
metabolic diseases
31 (24.41) 5 (21.74) 0.86 (0.29e2.51) 0.783
Diabetes mellitus 20 (15.75) 0 (0.00) e 0.044b
With complications 8 (6.30) 0 (0.00) e 0.609b
Diseases of the circulatory system 38 (29.92) 5 (21.74) 0.65 (0.23e1.88) 0.427
Heart failure 3 (2.36) 0 (0.00) e 1.000b
Diseases of the respiratory system 35 (27.56) 11 (47.83) 2.41 (0.97e5.96) 0.057
Respiratory tract infection 21 (16.54) 8 (34.78) 2.69 (1.01e7.15) 0.047 1.41 (0.49e4.04) 0.185
Respiratory failure 2 (1.57) 2 (8.70) 5.95 (0.79e44.59) 0.083 2.12 (0.21e20.96) 0.169
Diseases of the digestive system 17 (13.39) 3 (13.04) 0.97 (0.26e3.62) 0.965
Diseases of the genitourinary system 35 (27.56) 8 (34.78) 1.40 (0.55e3.60) 0.482
Urinary tract infection 18 (14.17) 4 (17.39) 1.27 (0.39e4.18) 0.689
Renal failure 15 (11.81) 4 (17.39) 1.57 (0.47e5.25) 0.462
Diseases of the nervous system 19 (14.96) 0 (0.00) e 0.046b
Diseases of the skin and
subcutaneous tissue
11 (8.66) 3 (13.04) 1.58 (0.41e6.18) 0.509
Diseases of the musculoskeletal
system and connective tissue
17 (13.39) 0 (0.00) e 0.076b
External causes of morbidity 44 (34.65) 4 (17.39) 0.40 (0.13e1.24) 0.112
Injury, poisoning and certain other
consequences of external causes
40 (31.50) 4 (17.39) 0.46 (0.15e1.43) 0.180
Systemic infection or organ failure 24 (18.90) 11 (47.83) 3.93 (1.55e9.98) 0.004 4.21 (1.38e12.81) 0.032
Immunocompromised status 29 (22.83) 9 (39.13) 2.17 (0.85e5.53) 0.104
Healthcare exposure
Emergency admission 98 (77.17) 20 (86.96) 1.97 (0.55e7.11) 0.299
Admission from healthcare facilities 13 (10.24) 3 (13.04) 1.32 (0.34e5.04) 0.689
Surgical specialty 60 (47.24) 9 (39.13) 0.72 (0.29e1.78) 0.474
TAR (days), median (IQR) 5 (1e25.5) 13 (2e20.5) 1.01 (0.98e1.03) 0.593
HDU stay 47 (37.01) 8 (34.78) 0.91 (0.36e2.30) 0.839
Duration of HDU stay (days),
median (IQR)
0 (0e2.5) 0 (0e2.5) 1.01 (0.97e1.06) 0.523
ICU stay 33 (25.98) 9 (39.13) 1.83 (0.72e4.63) 0.201
Duration of ICU stay (days),
median (IQR)
0 (0e0) 0 (0e0.5) 1.02 (0.94e1.11) 0.636
Hospitalization 53 (41.73) 11 (47.83) 1.28 (0.53e3.12) 0.587
Duration of hospitalization
(days), median (IQR)
17 (1e39) 18 (9e38) 1.00 (0.98e1.02) 0.799
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OR (95% CI) P-
value
aOR (95% CI) P-
value
Hospital transfer 23 (18.11) 4 (17.39) 0.95 (0.30e3.06) 0.934
Ward transfer 65 (51.18) 15 (65.22) 1.79 (0.71e4.51) 0.218
Invasive procedures
Any 52 (40.94) 12 (52.17) 1.57 (0.65e3.84) 0.319
Centesis 7 (5.51) 3 (13.04) 2.57 (0.61e10.78) 0.196
Ectomy 15 (11.81) 3 (13.04) 1.12 (0.30e4.23) 0.867
Transplantation 4 (3.15) 0 (0.00) e 1.000b
Catheterization 15 (11.81) 2 (8.70) 0.71 (0.15e3.34) 0.666
Urinary catheter 3 (2.36) 1 (4.35) 1.88 (0.19e18.89) 0.592
CVC 12 (9.45) 2 (8.70) 0.91 (0.19e4.38) 0.909
Dialysis or drainage 6 (4.72) 1 (4.35) 0.92 (0.11e7.99) 0.937
Endoscopic operation 8 (6.30) 3 (13.04) 2.23 (0.55e9.13) 0.264
Invasive ventilation 6 (4.72) 2 (8.70) 1.92 (0.36e10.16) 0.443
Other surgical procedures 17 (13.39) 3 (13.04) 0.97 (0.26e3.62) 0.965
OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio; CPO, carbapenemase-producing organisms; IQR, interquartile range; ICU,
intensive care unit; HDU, high dependency unit; TAR, time at risk; CVC, central venous catheter; e, not applicable.
a Number of survivors/non-survivors with the characteristic (percentage of survivors/non-survivors with the characteristic among all the
survivors/non-survivors investigated), unless stated otherwise.
b Fisher’s exact test.
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line with the national policy (76.1%) [14].
Similar to English data [15], the ‘big five’ carbapenemases
(VIM, NDM, KPC, OXA-48 and IMP) accounted for 96.7% of all 243
CPO isolates. In contrast to a London study that reported 34%
carbapenem-resistant non-fermenters [16], only 15.2% of all
the CPO isolates in Scotland were non-fermenters. This study
highlights another urgent public health threat, namely the
presence and transmission of CPO in the community. The
overall CA rate was 29.4% (62/211) and the incidence of CA
cases increased significantly over time (P<0.001). However,
the CA rate could have been overestimated due to possible
long-term persistence as stated above (up to 740 days) while
using 1 year from last hospitalization in the definition of CA. A
scoping review found that the percentage of either CA or
community-onset carbapenemase-resistant Enterobacterales
ranged from 0.04% to 29.5% [17], while a study reported the
rate of community-onset infections caused by CPE as 22.9%
[18]. Moreover, 69.4% of the 62 CA cases in the present study
were NDM/OXA-48 producers. The occurrence of OXA-48 pro-
ducers in the community is often a consequence of importa-
tions from endemic countries [19]. Also, it has been reported
that many NDM-1-positive patients in the UK had travelled to
India or Pakistan within the preceding year, or had links with
these countries [20]. Unfortunately, travel information is not
available in this study. Although enhanced data in the elec-
tronic reporting system submitted to the AMRHAI Reference
Unit include foreign travel, such information is filled in retro-
spectively on a voluntary basis following confirmation of car-
bapenemase production, and only 26% of records included
foreign travel information [15]. As travel is known to be asso-
ciated with increased risk for CPO, it is essential that infor-
mation on travel history, particularly foreign travel to endemiccountries, should be collected routinely in the community and
on admission to healthcare facilities.
Both host- and pathogen-related factors were reported to
be drivers of adverse outcomes. This study found that
advanced age, presence of carbapenemase-producing non-
fermenters, malignancy, respiratory tract infection, and sys-
temic infection or organ failure were associated with overall
30-day mortality. Advanced age has been reported to be a risk
factor for mortality by many researchers, as this group repre-
sents a vulnerable population for drug-resistant pathogens
[21e23]. Patients with malignancies usually have more fre-
quent exposure to health care such as immunocompromised
therapy (radiotherapy and chemotherapy), invasive proce-
dures (biopsies, bone marrow and spinal puncture) and longer
hospitalization. Respiratory infection has been described as a
risk factor for 30-day mortality in other studies [24,25].
Mucosal barrier injury in the respiratory tract and altered lung
tissue would decrease the capacity for bacterial clearance and
increase the probability of bacterial colonization and/or
infection. Multi-variate analysis revealed that both carrying
non-fermenters and systemic infection or organ failure were
independently associated with 30-day mortality. To the
authors’ knowledge, only one study has investigated the asso-
ciation between organisms and mortality, and this study did not
find any particular organism to be linked to mortality [26]. Both
virulence status and antimicrobial resistance may account for
this. First, some studies have demonstrated that virulence
determinants of Pseudomonas spp., such as the secretion of
toxins and elastase activity, could enhance pathogenicity
against host defence mechanisms, thus having an unfavourable
impact on outcome. In addition, biofilm formation on the
lumen of the respiratory tract could result in a higher risk of
mortality by posing greater resistance to antibiotics [27,28].
Second, carbapenem resistance in non-fermenters usually
S. Zhao et al. / Journal of Hospital Infection 110 (2021) 184e193192stems from a combination of beta-lactamases, porin mutations
and efflux pump overexpression, conferring reduced suscepti-
bility to antibiotics and implying fewer treatment options and
more treatment failure [29]. Systemic infection or organ failure
is a surrogate marker of critical illness which has been widely
reported as a predictor of poorer outcome [21,22,27,30].
Aggressive therapy and infection prevention and control
measures should be initiated rapidly in this population.
This study had a few limitations. First, no classification of
infection and colonization was made due to lack of clinical
symptoms and laboratory testing data. Second, data on com-
prehensive antimicrobial susceptibility and antimicrobial
treatment in hospital at individual level were not available.
Third, no genomic data were available to identify possible
clonal spread, outbreak and virulence. Further molecular study
is warranted to better understand the phylogeny and patho-
genicity of local CPO isolates.
In conclusion, the incidence of CPO in Scotland is relatively
low but is increasing rapidly. Awareness is required that
patients of advanced age, patients with systemic infection or
organ failure, and patients presenting with non-fermenters are
at higher risk of death from CPO. There is a need to continue
the existing Scottish CPE surveillance programme, and infec-
tion prevention and control measures for both Enter-
obacterales and non-fermenters warrant further consideration
in both health care and the community to help control the
spread of CPO. The findings of this study will also inform other
countries with similar epidemiological situations.
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